Xeris Biopharma Holdings (XERS) Total Non-Current Liabilities (2020 - 2026)

Xeris Biopharma Holdings has reported Total Non-Current Liabilities for 7 years, with the latest figure at $370.9 million in Q1 2026.

• For the quarter ending Q1 2026, Total Non-Current Liabilities rose 7.27% year-over-year to $370.9 million; the trailing twelve-month figure through Mar 2026 stood at $370.9 million (up 7.27% YoY), and the FY2025 full-year result was $361.4 million, up 3.06% from the prior year.
• Total Non-Current Liabilities for Q1 2026 stood at $370.9 million, up from $361.4 million in the prior quarter.
• The five-year high for Total Non-Current Liabilities was $370.9 million in Q1 2026, with the low at $214.5 million in Q2 2022.
• Historically, Total Non-Current Liabilities has averaged $315.5 million across 5 years, with a median of $339.7 million in 2024.
• Annual changes were most pronounced in 2022 — Total Non-Current Liabilities surged 65.28% — and 2025, when it declined 1.36%.
• Xeris Biopharma Holdings' Total Non-Current Liabilities stood at $273.6 million in 2022, then grew by 19.86% to $328.0 million in 2023, then increased by 6.92% to $350.7 million in 2024, then climbed by 3.06% to $361.4 million in 2025, then grew by 2.61% to $370.9 million in 2026.
• The last three Total Non-Current Liabilities figures came in at $370.9 million (Q1 2026), $361.4 million (Q4 2025), and $367.7 million (Q3 2025), per Business Quant data.